XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.23.2

Collaboration and License Agreement (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
Schedule of Revenue From Collaboration Agreements | The following table presents revenue from collaboration agreements:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
|  | (in thousands) |
Roche Collaboration and License Agreement |  | $ | 4,825 |  |  | $ | — |  |  | $ | 10,137 |  |  | $ | — |
Bristol Myers Squibb Collaboration and License Agreement |  |  | 14,951 |  |  |  | 679 |  |  |  | 15,317 |  |  |  | 1,087 |
Ono Collaboration Agreement |  |  | 10,473 |  |  |  | — |  |  |  | 10,473 |  |  |  | — |
Total revenue |  | $ | 30,249 |  |  | $ | 679 |  |  | $ | 35,927 |  |  | $ | 1,087 |
Roche |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
Schedule of Transaction Price Performance Obligations | Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations is as follows:
Performance obligation |  | Transaction price |
|  | (in thousands) |
Combined licenses |  | $ | 105,327 |
Completion of Continuing Trials |  |  | 30,585 |
Transfer of clinical trial materials |  |  | 2,714 |
Total transaction price |  | $ | 138,626 |
Schedule of Deferred Revenue |
Deferred revenue pertaining to the Roche Agreement |  | Completion of Continuing Trials |
|  | (in thousands) |
Balance as of December 31, 2022 |  | $ | 17,957 |
Increase in collaboration revenue receivable |  |  | 4,000 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | (5,312 | )
Balance as of March 31, 2023 |  | $ | 16,645 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | (4,825 | )
Balance as of June 30, 2023 |  | $ | 11,820 |
Classified as short-term |  | $ | 11,125 |
Classified as long-term |  |  | 695 |
Bristol-Myers Squibb Company |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
Schedule of Transaction Price Performance Obligations | Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:
Performance obligation |  | Transaction price |
|  | (in thousands) |
Research activities |  | $ | 6,405 |
Options to license druggable targets |  |  | 31,148 |
Options to license undruggable targets |  |  | 12,447 |
Total transaction price |  | $ | 50,000 |
Schedule of Deferred Revenue |
Deferred revenue pertaining to the BMS Agreement |  | Research activities |  | Options to license druggable targets |  | Options to license undruggable targets |  | Total |
|  | (in thousands) |
Balance as of December 31, 2022 |  | $ | 2,448 |  | $ | 12,459 |  | $ | 12,447 |  | $ | 27,354 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | (366 | ) |  | - |  |  | - |  |  | (366 | )
Balance as of March 31, 2023 |  | $ | 2,082 |  | $ | 12,459 |  | $ | 12,447 |  | $ | 26,988 |
Increase in collaboration revenue receivable |  |  | - |  |  | 1,250 |  |  | - |  |  | 1,250 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | (1,242 | ) |  | (13,709 | ) |  | - |  |  | (14,951 | )
Balance as of June 30, 2023 |  | $ | 840 |  | $ | - |  | $ | 12,447 |  | $ | 13,287 |
Classified as short-term |  | $ | 840 |  | $ | - |  | $ | 12,447 |  | $ | 13,287 |
Classified as long-term |  |  | - |  |  | - |  |  | - |  |  | - |
Ono Pharmaceutical Company Ltd |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
Schedule of Deferred Revenue |
Deferred revenue pertaining to the Ono Agreement |  | Research activities |
|  | (in thousands) |
Balance as of December 31, 2022 |  | $ | 10,473 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | - |
Balance as of March 31, 2023 |  | $ | 10,473 |
Recognition as revenue, as the result of performance obligations satisfied |  |  | (10,473 | )
Balance as of June 30, 2023 |  | $ | - |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |